Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

DAISY is a multicenter French clinical trial - NCT04132960 - aiming at assessing the efficacy of DS-8201a (Trastuzumab deruxtecan) monotherapy in patients with metastatic breast cancer.

Principal investigators

• Pr. Fabrice ANDRÉ (fabrice.andre@gustaveroussy.fr)
• Dr. Fernanda MOSELE (mariafernanda.mosele@gustaveroussy.fr)
• Dr. Lusque AMELIE (lusque.amelie@iuct-oncopole.fr)
• Dr. Thomas FILLERON (filleron.thomas@iuct-oncopole.fr)

Data coordinators

• Dr. Marta JIMENEZ (m-jimenez@unicancer.fr)
• Dr. Céline MAHIER (c-mahier@unicancer.fr)

Repository organisation

data

This folder contains instructions and documents to be signed to get access to the data. Please see data/README.md for more details.

code

Contains all the code supporting the analyses presented in the paper. See code/README.md for more details.

Contributors

• Bastien JOB https://github.com/aoumess bastien.job@gustaveroussy.fr
• Loic LE BESCOND https://github.com/loic-lb loic.le-bescond@centralesupelec.fr
• Yoann PRADAT https://github.com/ypradat yoann.pradat@gustaveroussy.fr